Activity Overview
The use of targeted therapy for patients with breast cancer harboring germline BRCA1/2 mutations has allowed for the precise tailoring of treatment that can improve outcomes. However, appropriate use of these agents requires that all patients undergo appropriate molecular testing and that each member of the multidisciplinary team understands how to interpret and act on these testing results.
This symposium is designed to bring participants up to date on the latest principles for germline BRCA testing and optimal incorporation of PARP inhibitors into the standard of care. These updates are given as presentations focused on the latest data and recommendations for timing and interpretation of testing results. Furthermore, practical considerations related to multidisciplinary treatment, genetic counseling, and the use of PARP inhibition in the context of treatment with curative intent will be discussed.
This educational activity is an archive of the live virtual symposium held at the 43rd Annual Miami Breast Cancer Conference® on March 6, 2026.
Target Audience
This educational activity is directed toward surgical oncologists, advanced practice professionals, nurses, pharmacists, and other health care practitioners who manage patients with breast cancer.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Describe the broadened criteria and clinical rationale for gBRCA testing beyond familial risk in breast cancer management
- Formulate appropriate treatment strategies based on accurate interpretation of genetic test results and consideration of patient-specific factors, including genetic status and clinical history
- Implement current guideline recommendations effectively for pre- and post-genetic test counseling, informed consent, and multidisciplinary collaboration in breast cancer treatment
Patrick I. Borgen, MD
Chairman, Department of Surgery
Director, Brooklyn Breast Cancer Program
Maimonides Medical Center
Brooklyn, NY
Disclosures: Patrick I. Borgen, MD, has no relevant financial relationships with ineligible companies.
Don S. Dizon, MD, FACP, FASCO
Jane F. Desforges Chair in Hematology and Oncology and Professor
of Medicine
Service Line Chief of Hematology and Oncology
Tufts University School of Medicine
Boston, MA
Disclosures: Advisor, Consultant, Fee-for-Service Recipient: AstraZeneca (ended), Medidata; Grant/Research Funding: Bristol Myers Squibb, Merck; Ownership interest in publicly traded companies: Doximity; Ownership interests in privately held companies: Midi
Kevin S. Hughes, MD, FACS
McKoy Rose Professor of Surgery
Medical University of South Carolina
Charleston, SC
Disclosures: Consultant: Olaparib Patent Dispute; Honoraria: AstraZeneca, Hologic (BioZorb, breast surgery devices), LabCorp (genetic testing), LetsGetChecked.com (genetic testing), TME/Aptitude Health (genetics education and consulting)
Banu Arun, MD, FASCO
Associate Professor and Deputy Chairman
Department of Breast Medical Oncology, Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX
Disclosures: Grant/Research Funding: CPRIT; Grant/Research Funding (paid to the institution): AstraZeneca
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
